RevvityRVTY
About: Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Employees: 11,500
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
159% more call options, than puts
Call options by funds: $19.6M | Put options by funds: $7.58M
2.42% more ownership
Funds ownership: 86.37% [Q1] → 88.79% (+2.42%) [Q2]
4% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 170
3% more capital invested
Capital invested by funds: $11.2B [Q1] → $11.5B (+$284M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]
7% less funds holding
Funds holding: 514 [Q1] → 477 (-37) [Q2]
46% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 81
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Wells Fargo Brandon Couillard 63% 1-year accuracy 5 / 8 met price target | 7%upside $130 | Equal-Weight Initiated | 27 Aug 2024 |
TD Cowen Dan Brennan 63% 1-year accuracy 19 / 30 met price target | 16%upside $141 | Buy Maintained | 30 Jul 2024 |
Citigroup Patrick Donnelly 69% 1-year accuracy 20 / 29 met price target | 19%upside $145 | Buy Maintained | 30 Jul 2024 |
JP Morgan Rachel Vatnsdal 59% 1-year accuracy 16 / 27 met price target | 1%downside $120 | Neutral Maintained | 30 Jul 2024 |
Barclays Luke Sergott 43% 1-year accuracy 16 / 37 met price target | 3%upside $125 | Equal-Weight Maintained | 30 Jul 2024 |
Financial journalist opinion
Based on 3 articles about RVTY published over the past 30 days